

OCT 03 2005

Applicant(s): S. Jayaraman  
Application No.: 10/696,174  
Examiner: S. Ghorbi**Amendments to the Claims**

Please amend the claims as follows:

Listing of Claims

1. (currently amended) A method for treating a patient with an intravascular implant, the method comprising:

diagnosing the patient as having a vascular disease;

~~determining a prevalent disease process in the pathology of the vascular disease;~~

~~selecting a first agent to treat or prevent the prevalent disease process of the vascular disease;~~

coating at least a portion of the intravascular implant with a therapeutically effective amount of an inhibitor of mTOR;

coating at least a portion of the intravascular implant with a therapeutically effective amount of an inhibitor of PDGF receptor ~~the first agent~~; and

implanting the intravascular implant in the patient to treat the vascular disease.

2-7. (canceled)

8. (currently amended) A method as defined in claim 1 2 wherein coating at least a portion of the intravascular implant with the inhibitor of PDGF receptor includes coating at least a portion of the intravascular implant with a polymer matrix.

9. (currently amended) A method as defined in claim 8 wherein the polymer matrix includes a biostable or bioabsorbable polymer.

10. (canceled)

Applicant(s): S. Jayaraman  
Application No.: 10/696,174  
Examiner: S. Gherbi

11. (currently amended) A method as defined in claim ~~9~~ 10 wherein the therapeutically effective amount of the inhibitor of PDGF receptor first agent is dispersed within the biostable or bioabsorbable polymer.

12. (canceled)

13. (currently amended) A method as defined in claim ~~1~~ 12 wherein the intravascular implant includes a primer layer upon which at least one of the coatings coating is applied.

14-15. (canceled)

16. (currently amended) A method as defined in claim ~~1~~ 13 further including a top coat applied over at least one of the coatings coating.

17-27. (canceled)

28. (currently amended) A method as defined in claim ~~1~~ 27, wherein coating the intravascular implant with the inhibitor of PDGF receptor and coating the implant with the inhibitor of mTOR are is performed at the procedure site and before the step of implanting the implant in the patient.

29-33. (canceled)

34. (new) A method as defined in claim 9, wherein the inhibitor of PDGF receptor is imatinib mesylate.

Applicant(s): S. Jayaraman  
Application No.: 10/696,174  
Examiner: S. Gherbi

35. (new) A method as defined in claim 34, wherein the imatinib mesylate is GLEEVEC.
36. (new) A method as defined in claim 1, wherein coating at least a portion of the intravascular implant with the inhibitor of mTOR includes coating at least a portion of the intravascular implant with a polymer matrix.
37. (new) A method as defined in claim 36, wherein the polymer matrix includes a biostable or bioabsorbable polymer.
38. (new) A method as defined in claim 37, wherein the therapeutically effective amount of the inhibitor of mTOR is dispersed within the biostable or bioabsorbable polymer.
39. (new) A method as defined in claim 37, wherein the inhibitor of mTOR is rapamycin.
40. (new) A therapeutic device for treating or preventing a disease of a patient, the device comprising an implant, an inhibitor of PDGF receptor disposed on the implant, and an inhibitor of mTOR disposed on the implant.
41. (new) A device as defined in claim 40 further including a polymeric coating associated with the implant, the polymer coating carrying the inhibitor of PDGF receptor.
42. (new) A device as defined in claim 41 wherein the polymeric coating includes a biostable or bioabsorbable polymer.
43. (new) A device as defined in claim 42 wherein the inhibitor of PDGF receptor is imatinib mesylate.

Applicant(s): S. Jayaraman  
Application No.: 10/696,174  
Examiner: S. Gherbi

44. (new) A device as defined in claim 43 wherein the imatinib mesylate is GLEEVEC.
45. (new) A device as defined in claim 40 further including a first polymeric coating associated with the implant, the first polymeric coating carrying the inhibitor of mTOR.
46. (new) A device as defined in claim 45 wherein the first polymeric coating includes a biostable or bioabsorbable polymer.
47. (new) A device as defined in claim 46 wherein the inhibitor of mTOR is rapamycin.
48. (new) A device as defined in claim 47 further including a second polymeric coating associated with the implant, the second polymeric coating carrying the inhibitor of PDGF receptor.
49. (new) A device as defined in claim 48 wherein the second polymeric coating includes a biostable or bioabsorbable polymer.
50. (new) A device as defined in claim 50 wherein the inhibitor of PDGF receptor is GLEEVEC.
51. (new) A device as defined in claim 51 wherein the implant is selected from the group consisting of a balloon catheter, stent, stent graft, drug delivery catheter, atherectomy device, filter, scaffolding device, anastomotic clip, anastomotic bridge, suture material, wire, embolic coil and a combination thereof.